AstraZeneca plc., is a global, innovation-driven biopharma major formed through the merger of Swedish Astra AB and British Zeneca Group Plc in 1999.
- In June 2020, Accent Therapeutics, Inc. and AstraZeneca collaborate to discover, develop and commercialize therapeutics targeting RMPs for the treatment of cancer. Under the terms, Accent will be responsible for R&D activities through to the end of Ph I clinical trials, thereafter AstraZeneca will lead development and commercialization activities, with Accent having the option to jointly develop and commercialize with AstraZeneca in the US. Also, Accent to receive a $55 Mn USD upfront payment and is eligible for up to approx. $1.1B USD in total additional milestones, plus tiered royalties, under co-development and co-commercialization arrangement.
- In July 2020, AstraZeneca entered into its second collaboration with Daiichi Sankyo, for the development of DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC), Under the terms, AstraZeneca paid Daiichi Sankyo an upfront payment of $1 bn and additional conditional amounts of up to $1 bn for the successful achievement of regulatory approvals and up to $4bn for sales-related milestones. AstraZeneca will equally share the cost of development and commercialization of DS-1062 along with any profits earned from its sale, except for Japan where Daiichi will have full control.
- In Mar 2019, AstraZeneca signed global collaboration deal with Daiichi Sankyo for its proprietary antibody-drug conjugate trastuzumab deruxtecan (DS-8201), to jointly develop and commercialize trastuzumab deruxtecan worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Under the terms, AstraZeneca paid Daiichi Sankyo an upfront payment of $1.35bn and contingent payments of up to $5.55bn including $3.8bn for potential successful achievement of future regulatory and other milestones, as well as $1.75bn for sales-related milestones.
- In Nov 2019, Aravive and AstraZeneca signed clinical trial collaboration to jointly fund an investigator-sponsored Phase 1/2 clinical trial of AVB-500 in combination with durvalumab, a PD-L1 inhibitor, in patients with platinum-resistant, recurrent epithelial ovarian cancer has initiated and is recruiting patients.
- In Nov 2019, Antengene Corporation entered into a licensing agreement with AstraZeneca under, which Antengene obtained the worldwide exclusive rights to develop, manufacture and commercialize selective ERK1/2 inhibitor AZD0364. Financial details and other terms remains undisclosed.
- In Nov 2019, Abbisko Therapeutics Co., Ltd. in-licensed the drug’s global rights of clinical-stage product, AZD4547 (now ABSK-091) an FGFR Inhibitor, currently in Ph II studies for the treatment of cholangiocarcinoma, bladder and other types of cancers from Astrazeneca plc.
- In May 2019, Transgene and AstraZeneca enter into exclusive license option agreement to develop 5 novel oncolytic immunotherapies based on Transgene Invir.IOTM platform. Under the terms, Transgene is to receive $10 Mn upon signing and additional pre-clinical success milestones of up to $3 Mn. Transgene is eligible to receive an option exercise payment on each candidate in the event AstraZeneca exercises its license option, as well as development and commercial milestones and royalties.
- In Oct 2018, Innate with an expanded deal with AstraZeneca, acquired US and EU commercial rights to AstraZeneca’s FDA-approved Lumoxiti (moxetumomab pasudotox-tdfk) for hairy cell leukemia. In turn, AstraZeneca obtained full oncology rights to the first-in-class humanised anti-NKG2A antibody, monalizumab, thus expanding its earlier 2015 partnership with Innate. AstraZeneca also gains option rights to IPH5201, an antibody targeting CD39, as well as four pre-clinical molecules from Innate’s pipeline. Selected molecules include IPH43, an anti-MICA/B antibody drug conjugate program, and the anti-Siglec 9 antibody program. AstraZeneca also purchased newly-issued equity stake of 9.8% in Innate Pharma.
- In July 2017, AstraZeneca and Merck & Co., entered a global strategic oncology collaboration to co-develop and co-commercialise AstraZeneca’s Lynparza (olaparib) for multiple cancer types jointly, both as monotherapy and in combination with other potential medicines. The companies will also jointly develop and commercialise AstraZeneca’s selumetinib, an oral, potent, selective inhibitor of MEK. Under the terms, AstraZeneca and Merck to share the development and commercialisation costs and profit for Lynparza and selumetinib equally AstraZeneca will continue to manufacture Lynparza and selumetinib and Merck will pay AstraZeneca up to $8.5 billion in total consideration, including $1.6 billion upfront, $750 Mn for certain license options and up to $6.15 billion contingent upon successful achievement of future regulatory and sales milestones.
- In Jan 2016, AstraZeneca and Moderna, extended their earlier 2013 signed collaboration, to further develop two specific immuno-oncology programmes, based on promising pre-clinical data. Moderna to lead preclinical development, while AstraZeneca will be responsible for early clinical development, led by MedImmune, and Moderna and AstraZeneca will share the costs of late-stage clinical development. The two companies will co-commercialise resulting products in the US under a 50:50 profit sharing arrangement. AstraZeneca will lead ex-US commercialisation efforts, with Moderna receiving tiered royalties up to substantial double digits on ex-US sales. MEDI1191, an investigational IL-12 iTu immunotherapy with a checkpoint inhibitor, is presently in Ph I clinical trials for the treatment of solid tumours is under this collaboration with Astrazeneca on 50-50 global profit sharing.
- In 2013, AstraZeneca signed an agreement with Moderna and agreed to pay up to $420 Mn to get its hands on up to 40 candidates in cardiovascular and kidney diseases and certain cancers for 5 years.
In Aug 2015, MedImmune acquired exclusive rights to Inovio’s INO-3112 immunotherapy, currently in Ph I/II clinical trials for cervical and head and neck cancers. Under the terms, MedImmune paid $27.5 Mn as upfront and upto $700 Mn in total. MedImmune intends to study INO-3112 in combination with selected immunotherapy molecules within its pipeline in HPV-driven cancers. - In Aug 2015, AstraZeneca acquired exclusive global rights to develop, manufacture, and commercialize Heptares Therapeutics’ immuno-oncology candidate HTL-1071, designed to fight cancer by blocking the adenosine A2A receptor. Under the terms AstraZeneca paid an initial $10 Mn for exclusive global rights to HTL-1071,and could pay more than $500 Mn on its commercial success.
In July 2015, Astrazenca sold global marketing rights of Caprelsa approved for Thyroid cancer, to Genzyme (Sanofi) in payments upto $300 Mn USD. - In Apr 2015, Innate Pharma and AstraZeneca announce global co-development and commercialisation agreement for IPH2201 in combination with MEDI4736 and access to IPH2201 in monotherapy and other combinations in certain areas. The financial terms of the signed agreement include cash payments of up to $1.275 billion to Innate as well as double digit royalties on sales.
- In Apr 2015, MedImmune, entered into an exclusive agreement with Celgene, for the development and commercialisation of MEDI4736 across a range of blood cancers. Under the terms, Celgene make an upfront payment of $450 Mn to AstraZeneca and will lead on development across all clinical trials within the collaboration and will take on all R&D costs until the end of 2016, after which they will take on 75 percent of these costs. Celgene will also be responsible for global commercialisation of approved treatments while AstraZeneca will continue to manufacture and receive sales share on the worldwide sales in haematological indications.
- In Oct 2013, AstraZeneca entered into an agreement with Janssen Pharmaceuticals to co-promote Abiraterone acetate in Japan.
- In Oct 2013, MedImmune (AstraZeneca) entered into a collaboration agreement with ADC Therapeutics to jointly develop two of ADCT’s antibody-drug conjugate programs in preclinical development.
In Sep 2013, AstraZeneca and Merck & Co, entered into worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase (MK-1775). Adavosertib/MK-1775 is currently being evaluated in Phase IIa clinical studies in combination with standard of care therapies for the treatment of patients with certain types of ovarian cancer. Under the terms, Merck recieved $50 Mn upfront fee and is eligible to receive future payments tied to development and regulatory milestones plus sales-related payments and tiered royalties. AstraZeneca will be responsible for all future clinical development, manufacturing and marketing. - In Apr 2013, BIND and AstraZeneca entered into a strategic collaboration to develop and commercialize an Accurin™ based therapies for cancer.
- In Dec 2012, AstraZeneca and Isis Pharmaceuticals signed a strategic alliance for the discovery and development of novel generation antisense therapeutics against five cancer targets. Under the terms AstraZeneca paid $31 Mn in upfront and acquired an exclusive license to develop and commercialise ISIS-STAT3Rx and a pre-clinical program as well as an option to license products developed under a separate research program.
- AstraZeneca is in collaboration with Array Biopharma for the development and commercialization of small molecule MEK inhibitors.
- AstraZeneca is in co-promotion agreement with Daiichi Sankyo in Japan for Denosumab/Prolia®, approved for SRE in cancer..
Page 2 of 3
